Banyan Capital Management Inc. Reduces Position in Henry Schein, Inc. $HSIC

Banyan Capital Management Inc. decreased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 27.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 98,882 shares of the company’s stock after selling 36,875 shares during the period. Henry Schein makes up about 3.1% of Banyan Capital Management Inc.’s portfolio, making the stock its 12th biggest holding. Banyan Capital Management Inc.’s holdings in Henry Schein were worth $7,288,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hsbc Holdings PLC grew its stake in Henry Schein by 40.7% during the 1st quarter. Hsbc Holdings PLC now owns 173,858 shares of the company’s stock valued at $12,765,000 after purchasing an additional 50,308 shares during the last quarter. Staley Capital Advisers Inc. raised its stake in shares of Henry Schein by 12,115.2% in the first quarter. Staley Capital Advisers Inc. now owns 450,740 shares of the company’s stock worth $33,220,000 after purchasing an additional 447,050 shares during the last quarter. Stenger Family Office LLC acquired a new stake in shares of Henry Schein during the first quarter worth about $1,807,000. Berger Financial Group Inc boosted its position in Henry Schein by 69.3% in the first quarter. Berger Financial Group Inc now owns 80,790 shares of the company’s stock valued at $5,954,000 after buying an additional 33,070 shares during the last quarter. Finally, K.J. Harrison & Partners Inc purchased a new stake in Henry Schein in the first quarter valued at approximately $1,253,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Buying and Selling at Henry Schein

In related news, Director William K. Daniel purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $69.19 per share, with a total value of $691,900.00. Following the purchase, the director owned 20,000 shares of the company’s stock, valued at $1,383,800. This represents a 100.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.89% of the stock is currently owned by company insiders.

Henry Schein Price Performance

Shares of NASDAQ:HSIC traded up $0.54 during midday trading on Friday, reaching $84.40. 1,156,510 shares of the company’s stock traded hands, compared to its average volume of 1,187,323. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $89.29. The company has a market cap of $9.61 billion, a P/E ratio of 25.50, a PEG ratio of 1.63 and a beta of 0.81. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. The company has a fifty day simple moving average of $78.04 and a two-hundred day simple moving average of $77.34.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The company had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts predict that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on HSIC shares. Mizuho reduced their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a report on Monday, May 4th. Citigroup began coverage on Henry Schein in a research report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price objective on the stock. Wall Street Zen lowered shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Finally, UBS Group reissued a “neutral” rating and set a $85.00 price target (down from $87.00) on shares of Henry Schein in a report on Wednesday, May 6th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $87.64.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.